-
2022-12-20
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
-
2022-10-14
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) trial in chronic obstructive pulmonary disease
-
2022-08-09
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its top-line Phase 3 ENHANCE-2 (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD
-
2022-06-27
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs
-
2022-06-09
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
-
2020-10-21
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
Neumentum Inc. announced that the company has entered into a license agreement with Nuance Biotech Co. Ltd providing Nuance with the exclusive rights to develop and commercialize Neumentum's novel ketorolac for IV infusion (NTM-001) in China.
- 1
- 2
Contact PR
